Abertay Tea for Cardiovascular Health During Menopause

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age45-74
SponsorAbertay University

About this trial

The regular consumption of seaweed, as observed in Japan, is associated to a reduced cardiovascular risk and prolonged life expectancy. Interventional studies have shown that brown seaweed consumption can reduce blood pressure, improve glycaemic control and lipoprotein profiles, although this varies with population, dose, duration and the type of seaweed. Brown seaweed appears the most promising to improve cardiovascular risk, due to the presence of specific antioxidants (polyphenols called phlorotannins), pigments (fucoxanthin) and fibre (alginate, fucoidan).

Women see their cardiovascular risk greatly increased when they reach menopause, and seaweed consumption may provide benefits for this population. In the UK, 98% of UK residents drink tea daily (Source UKTIA), with English breakfast tea being the most popular. Providing a tea enriched with beneficial compounds has the potential to improve cardiovascular health in a wide range of the population, including postmenopausal women. Abertay university (Dundee, UK) has recently developed an English Breakfast tea enriched with fermented seaweed, which was found to taste like English breakfast tea. We hypothesise that the consumption of 3 cups a day of the Abertay-developed Tea (AberTea) for 8 weeks, with each tea bag containing 1g of fermented seaweed, will improve vascular function and cardiovascular risk factors in postmenopausal women.

Eligibility criteria

Qualifiers

Postmenopausal status: no menstrual period over the last 12 months

Regular tea drinkers (at least once a week), willingness to consume 3 cups of English breakfast tea per day for 8 weeks

BMI between 18.5 and 39.99 kg/m2

Disqualifiers

Reported history of CVD (myocardial infarction, angina, venous thrombosis, stroke, dyslipidemia), diabetes (or fasting glucose ≥ 6.1 mmol/L), kidney, liver or bowel disease.

Recent history of cancer (<1y)

History indicative of a congenital or acquired platelet or haemostatic defect.

Presence of gastrointestinal disorder or use of drug, which is likely to alter gastrointestinal motility or nutrient absorption.

Trial design

Treatments tested in this trial

  • Nutritional intervention with Fermented Seaweed Enriched English Breakfast Tea
  • Nutritional intervention with Control English Breakfast Tea

Treatment groups

44 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Abertay University

Lead sponsor

Oshun Labs Ltd

Collaborator

UK Research and Innovation

Collaborator